# Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases

> **NCT01508000** · PHASE2 · TERMINATED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 44 (actual)

## Conditions studied

- Colorectal Cancer Metastatic
- Liver Metastases
- KRAS Wild Type Colorectal Cancer

## Interventions

- **DRUG:** FOLFOX6
- **BIOLOGICAL:** Bevacizumab
- **BIOLOGICAL:** Panitumumab
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT01508000
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Low or poor accrual
- **Last updated:** 2016-10-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01508000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01508000, "Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01508000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*